medigraphic.com
ISSN 1995-9427 (Print)

2021, Number 2

<< Back Next >>

Invest Medicoquir 2021; 13 (2)

Thromboprophylaxis and anticoagulation strategies in pediatric patients with COVID-19

Porta DM, Salvato DA, Alvaré AL, Melo VM, Lobato PD, González CI

Language: Spanish
References: 31
Page:
PDF size: 173.95 Kb.


ABSTRACT

SARS-CoV-2 (COVID-19) disease is an emerging disease of global concern. The pathophysiology, spectrum of manifestations and complications have not been fully described, among which coagulopathy with a prothrombotic phenotype associated with a poor prognosis stands out. Despite the fact that there are published works, the controversy remains regarding the benefit of prophylactic or therapeutic anticoagulation. That is why this review aims to identify which behaviors to date are the most appropriate for anticoagulation treatment and which criteria we must bear in mind according to the current evidence in the literature. Covid-19 is a disease of which much is still unknown, and in pediatric ages this ignorance increases even more, so the study of clinical and laboratory indicators are elements that can help prevent thromboembolic complications and to the treatment of the same in case they appear.


REFERENCES

  1. López González Lissette del Rosario, Noda Albelo Amauri Lázaro, Castro Pacheco Berta Lidia, et al, Caracterización clínico epidemiológica de 183 niños cubanos con infección por SARS-CoV-2. Revista Cubana de Pediatría. 2020;92(Supl. especial): e1256

  2. Malik YA. Properties of Coronavirus and SARS-CoV-2. Malaysian J Pathol. 2020; 42(1):3-11.

  3. Jiménez-Soto Rodolfo, Montiel-Romero Santiago, Neme-Yunes Yvette,et al, Estrategias de anticoagulación en pacientes con COVID-19.

  4. Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, et al. Prevalence and severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Virol 2020; 127: 104371. https://doi.org/10.1016/j.jcv.2020.104371.

  5. García-Salido Alberto, Antón Jordi, Martínez - Pajares José David, et al. Documento español de consenso sobre diagnóstico, estabilización y tratamiento del síndrome inflamatorio multisistémico pediátrico vinculado a SARS-CoV-2 (SIM-PedS)

  6. COVID-19/Informe n.◦ 33. Análisis de los casos de COVID-19 hasta el 10 de mayo en España a 29 de mayo de 2020.pdf. 2020 [consultado 30 30 Jun 2020]. Disponible: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/ INFORMES/Informes.

  7. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 2020; 127: 104362. https://doi.org/10.1016/j.jcv.2020.104362

  8. Emergency preparedness and response Multisystem Inflamatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease. 2020. Disponible en: https://emergency.cdc.gov/coca/calls/2020/callinfo 051920. asp.

  9. COVID-19/Informe n.◦ 33. Análisis de los casos de COVID-19 hasta el 10 de mayo en España a 29 de mayo de 2020.pdf. 2020 [consultado 30 30 Jun 2020]. Disponible: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes.

  10. Estudio ENE-COVID19: segunda ronda estudio nacional de sero-epidemiología de la infección por SARSCoV- 2 en España. 2020 [consultado 16 Jun 2020]. Disponible en: https://www.mscbs.gob.es/ciudadanos/enecovid/docs/ESTUDIO ENE-COVID19 SEGUNDA RONDA INFORME PRELIMINAR.pdf.

  11. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost. 2020; 18:786–7, doi: 10.1111/jth.14781.

  12. López-Reyesa Raquel, Oscullo Grace, Jiménez David, et al. Riesgo trombótico y COVID-19: revisión de la evidencia actual para una mejor aproximación diagnóstica y terapéutica

  13. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18:844–7, doi: 10.1111/jth.14768.

  14. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020:4---6, https://doi.org/10.1055/s-0040- 1710018.

  15. Terpos E, Ntanasis Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020, http://dx.doi.org/10.1002/ajh.25829. In press.

  16. Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: A pooled analysis. Thromb Haemost. 2020; 120:876–8, doi: 10.1055/s-0040-1709650.

  17. Moreno G, Carbonell R, Bodí M, et al, Revisión sistemática sobre la utilidad pronóstica del dímero-D, coagulación intravascular diseminada y tratamiento anticoagulante en pacientes graves con COVID-19. http://www.medintensiva.org/

  18. Ong JSM, Tosoni A, Kim Y, Kissoon N, et al. Coronavirus Disease 2019 in Critically Ill Children: A Narrative Review of the Literature. Pediatr Crit Care Med. 2020 Apr 7. [Acceso: 20 de abril de 2020]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/32265372.

  19. Taffarela Pedro, Jorro Baróna Facundo. El paciente pediátrico crítico con COVID-19. Puesta al día.

  20. Vicente Carlos de Juan Carlos, Barrio Slocker María, Hofheinz Belda Sylvia, et al, Documento de manejo clínico del paciente pediátrico con infección por sars-cov-2 en cuidados intensivos.

  21. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost. 2020; 18:786–7, doi: 10.1111/jth.14781.

  22. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID- 19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4, doi: 10.1016/S0140-6736(20)30628-0.

  23. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18:844---7, https://doi.org/10.1111/jth.14768.

  24. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020:4---6, https://doi.org/10.1055/s-0040- 1710018.

  25. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1 MERS-CoV and lessons from the past. J Clin Virol. 2020; 127:104362, https://doi.org/10.1016/j.jcv.2020.104362.

  26. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020. In press doi: 10.1182/blood.2020006000.

  27. Evans CE, Bendahl PO, Belting M, Branco C, Johnson RS. Diverse roles of cell-specific hypoxia-inducible factor 1 in cancer-associated hypercoagulation. Blood. 2016; 127:1355–60, doi: 10.1182/blood-2015-09-671982.

  28. Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020;50:72-81.

  29. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. Chest. 2020;158:1143-63.

  30. Loi M, Branchford B, Kim J, Self C, Nuss R. COVID‐19 anticoagulation recommendations in children. Pediatr Blood Cancer [Internet]. 2020. [citado 5 de octubre de 2020]; 67. Disponible en: https://onlinelibrary.wiley.com/doi/10.1002/pbc.28485

  31. AEPED. Consenso nacional sobre diagnóstico, estabilización y tratamiento del Síndrome Inflamatorio Multisistémico Pediátrico vinculado a SARS-CoV-2 (SIM-PedS). [Internet]. Disponible en: https://www.aeped.es/sites/default/files/aep.sim-peds.v1.pdf




2020     |     www.medigraphic.com